Early recovery of CMV immunity after HLA-haploidentical hematopoietic stem cell transplantation as a surrogate biomarker for a reduced risk of severe infections overall

Bone Marrow Transplant. 2015 Sep;50(9):1262-4. doi: 10.1038/bmt.2015.132. Epub 2015 Jun 15.

M Noviello¹, A Forcina^{2

3}, V Veronica⁴, R Crocchiolo⁵, M T L Stanghellini², M Carrabba², R Greco², L Vago^{2

6}, F Giglio², A Assanelli², M R Carbone¹, Z Magnani¹, F Crippa⁷, C Corti², M Bernardi², J Peccatori², C Bordignon^{3

4}, F Ciceri², C Bonini¹, A Bondanza^{3

8}

¹ Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Hospital Scientific Institute, Milan, Italy.
² Hematology and Bone Marrow Transplantation Unit, Division of Regenerative Medicine, Stem Cell and Gene Therapy, San Raffaele Hospital Scientific Institute, Milan, Italy.
³ Vita-Salute San Raffaele University, Milan, Italy.
⁴ MolMed S.p.a, Milan, Italy.
⁵ Department of Hematology, Humanitas Clinical Institute, Milan, Italy.
⁶ Unit of Molecular and Functional Immunogenetics, Division of Regenerative Medicine, Stem Cell and Gene Therapy, San Raffaele Hospital Scientific Institute, Milan, Italy.
⁷ Infectious Disease Unit, San Paolo Hospital, University of Milan, Milan, Italy.
⁸ Innovative Immunotherapies Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Hospital Scientific Institute, Milan, Italy.

No abstract available

Publication types